trending Market Intelligence /marketintelligence/en/news-insights/trending/wi904Z9HRiqPX0zftrUwbA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Oragenics prices $12.5M offering of stock, warrants

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Oragenics prices $12.5M offering of stock, warrants

Oragenics Inc. priced an underwritten public offering of shares and warrants at 75 cents per share and accompanying warrants.

The Tampa, Fla.-based antibiotics maker expects to raise gross proceeds of about $12.5 million.

Oragenics is offering 16,666,668 common shares, short-term warrants to buy up to 8,333,334 shares and long-term warrants to buy up to 8,333,334 shares.

The underwriter has an option to buy up to 2.5 million additional shares, short-term warrants to buy 1,250,000 shares and long-term warrants to buy 1,250,000 common shares at the public offering price.

The short-term warrants will be immediately exercisable at exercise price of 75 cents per share. They will expire 18 months after issuance or 21 trading days after Oragenics releases top-line data from a phase 2 study of its drug candidate AG013, whichever comes earlier.

AG013 is a potential treatment for oral mucositis, or mouth sores, in cancer patients. Oral mucositis is a common complication of cancer treatment.

The long-term warrant will be immediately exercisable, at an exercise price of 90 cents per common share and will expire five years after issue date.

Oragenics plans to use net proceeds to fund research of AG013 as well as for preclinical development of the company's lantibiotics program and other clinical trials. Net proceeds will also be used for working capital and general corporate purposes.

The offering is expected to close on or about March 25.

H.C. Wainwright & Co. is the sole book-running manager for the offering.